BLRX Stock Summary and Trading Ideas (Bioline Rx | NASDAQ:BLRX)

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Bioline Rx trades on the NASDAQ stock market under the symbol BLRX.

As of April 24, 2024, BLRX stock price declined to $0.61 with 757,073 million shares trading.

BLRX has a beta of 2.36, meaning it tends to be more sensitive to market movements. BLRX has a correlation of 0.09 to the broad based SPY ETF.

BLRX has a market cap of $49.00 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BLRX stock traded as high as $6.34 and as low as $.55.

The top ETF exchange traded funds that BLRX belongs to (by Net Assets): APIE.

BLRX has underperformed the market in the last year with a price return of -45.8% while the SPY ETF gained +24.2%. BLRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -55.3% and -13.4%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

BLRX support price is $.59 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLRX stock will trade within this expected range on the day.